An Observational Study Investigating the Effectiveness of Pravastatin on Renal Function in Korean Dyslipidemic Patients With Type 2 Diabetes

Inclusion Criteria: * Participants with Type 2 diabetes (currently using an antidiabetic drug or satisfying diagnostic criteria of diabetes as defined by American Diabetes Association) * Participants with dyslipidemia (currently using an antidyslipidemic drug or satisfying the Health Insurance Review \& Assessment Service insurance coverage treatment criteria\*) for whom drug treatment with pravastatin is confirmed * Participants determined to be eligible as subjects at the discretion of the investigator * Participants who voluntarily provided written consent using the Informed Consent Form on Use of Information Exclusion Criteria: * Participants who had administered pravastatin prior to study participation * Participants with hypersensitivity to the investigational product or its history * Participants with an active liver disease or persistent elevation of transaminase with an unknown cause * Pregnant woman or women with childbearing potential, breastfeeding mothers * Children * Participants with severe hepatic or renal insufficiency * Participants with myopathy * Participants with cholestasis * Participants with hypercholesterolemia due to hyperalphalipoproteinemia accompanied by HDL cholesterol elevation * Participants with a genetic problem such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption